共被期刊论文引用了2次
您的检索式：您选中1篇文献正在查看引证文献汇总
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Potential targeted therapy and diagnosis based on novel insight into growth factors,receptors,and downstream effectors in acute kidney injury and acute kidney injury-chronic kidney disease progression显示文摘Acute kidney injury(AKI)is defined as a rapid decline in renal function and is characterized by excessive renal inflammation and programmed death of resident cells.AKI shows high morbidity and mortality,and severe or repeated AKI can transition to chronic kidney disease(CKD)or even end-stage renal disease(ESRD);however,very few effective and specific therapies are available,except for supportive treatment.Growth factors,such as epidermal growth factor(EGF),insulin-like growth factor(IGF),and transforming growth factor-β(TGF-β),are significantly altered in AKI models and have been suggested to play critical roles in the repair process of AKI because of their roles in cell regeneration and renal repair.In recent years,a series of studies have shown evidence that growth factors,receptors,and downstream effectors may be highly involved in the mechanism of AKI and may function in the early stage of AKI in response to stimuli by regulating inflammation and programmed cell death.Moreover,certain growth factors or correlated proteins act as biomarkers for AKI due to their sensitivity and specificity.Furthermore,growth factors originating from mesenchymal stem cells(MSCs)via paracrine signaling or extracellular vesicles recruit leukocytes or repair intrinsic cells and may participate in AKI repair or the AKI-CKD transition.In addition,growth factor-modified MSCs show superior therapeutic potential compared to that of unmodified controls.In this review,we summarized the current therapeutic and diagnostic strategies targeting growth factors to treat AKI in clinical trials.We also evaluated the possibilities of other growth factorcorrelated molecules as therapeutic targets in the treatment of AKI and the AKI-CKD transition. | Li Gao Xiang Zhong Juan Jin Jun Li Xiao-ming Meng | 2020 | Signal Transduction and Targeted Therapy2020，5，1： | 6 |
| 2 | Targeted chemotherapy for subcutaneous and orthotopic non-small cell lung tumors with cyclic RGD-functionalized and disulfide-crosslinked polymersomal doxorubicin显示文摘Lung cancer, with its high mortality and increasing morbidity, has become one of the most lethal malignancies worldwide. Here, we developed cyclic RGD peptide-directed and disulfide-crosslinked polymersomal doxorubicin (cRGD-PS-Dox) as a targeted chemotherapy for human non-small cell lung cancer (NSCLC). Notably, cRGD-PS-Dox exhibited a high Dox loading (15.2 wt.%), small hydrodynamic diameter (96 nm), superb stability, prominent targetability to αvβ3 integrin overexpressing A549 human lung cancer cells, and rapid release of the drug into nuclei, leading to a significantly improved antitumor activity compared with the control groups, i.e., PS-Dox and Lipo-Dox (a liposome injection employed in clinical settings). The pharmacokinetic and biodistribution results for cRGD-PS-Dox revealed similar elimination half-lives but two-fold enhanced tumor accumulation compared with PS-Dox and Lipo-Dox. Intriguingly, cRGD-PS-Dox effectively suppressed the growth of A549 lung tumors in both subcutaneous and orthotopic models with minimal adverse effects at a Dox dose of 12 mg/kg, leading to significant survival benefits compared with PS-Dox and Lipo-Dox. This αvβ3 integrin-targeting multifunctional polymersomal doxorubicin is highly promising for targeted chemotherapy of human NSCLC. | Yan Zou Jingjing Wei Yifeng Xia Fenghua Meng Jiandong Yuan Zhiyuan Zhong | 2018 | Signal Transduction and Targeted Therapy2018，3，1： | 2 |
您所在的机构暂未开通此部分的功能，请联系管理员